Compare the pathways of imported versus indigenous vaccine development in India, citing the Qdenga and DengiAll examples.

Dengue remains one of India's heaviest vector-borne disease burdens, with over 2.33 lakh cases reported in 2024 [3]. India's response reveals two parallel vaccine pathways — the import-and-approve route, seen in CDSCO's July 2026 marketing authorisation of Takeda's Qdenga® [1], and the indigenous development route of DengiAll by ICMR–Panacea Biotec [2].

Regulatory and development pathway

• Imported route: Qdenga arrived with a global evidence base — approvals in 42 countries and WHO prequalification — requiring CDSCO only to bridge it with a Phase III safety and immunogenicity study in the Indian population under the Drugs and Cosmetics Act, 1940 [1].
• Indigenous route: DengiAll must traverse the full ladder — Phase 1/2 (completed 2018–19) to a Phase 3 efficacy trial across 19 sites in 18 States/UTs with over 10,335 participants, with two-year follow-up [2].

Speed versus self-reliance

• Import compresses time-to-availability; a proven tetravalent vaccine with 24 million doses distributed globally became accessible for ages 4–60 within months of dossier review [1].
• Indigenisation is slower but builds domestic manufacturing depth, using the NIH-derived TV003/TV005 strain adapted by an Indian firm [2] — advancing Atmanirbhar Bharat in biopharma.

Cost, access and supply security

• Imported vaccines carry foreign-exchange costs and are typically confined to the private market, limiting equity.
• An indigenous, ICMR-funded candidate offers price control and assured supply, easing integration into the National Vector Borne Diseases Control framework [3].

Evidence fit

• Global trial populations may not fully mirror India's serotype mix; DengiAll's India-wide trial generates directly applicable efficacy data [2].

The two pathways are complementary rather than competing: imports deliver immediate protection while indigenous R&D secures long-term affordability and sovereignty. India should therefore use Qdenga to blunt the present outbreak burden, while strengthening ICMR-led trials, regulatory capacity in CDSCO and domestic manufacturing — converting a stopgap import into durable public-health self-reliance aligned with SDG-3.